- Home
- STRO vs BMEA Comparison
STRO vs BMEA Comparison
Compare STRO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- BMEA
- Stock Information
- Founded
- STRO 2003
- BMEA 2017
- Country
- STRO United States
- BMEA United States
- Employees
- STRO N/A
- BMEA N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- BMEA Health Care
- Exchange
- STRO Nasdaq
- BMEA Nasdaq
- Market Cap
- STRO 172.8M
- BMEA 145.0M
- IPO Year
- STRO 2018
- BMEA 2021
- Fundamental
- Price
- STRO $2.05
- BMEA $3.80
- Analyst Decision
- STRO Strong Buy
- BMEA Buy
- Analyst Count
- STRO 7
- BMEA 13
- Target Price
- STRO $12.14
- BMEA $37.25
- AVG Volume (30 Days)
- STRO 1.4M
- BMEA 1.1M
- Earning Date
- STRO 11-13-2024
- BMEA 10-29-2024
- Dividend Yield
- STRO N/A
- BMEA N/A
- EPS Growth
- STRO N/A
- BMEA N/A
- EPS
- STRO N/A
- BMEA N/A
- Revenue
- STRO $160,955,000.00
- BMEA N/A
- Revenue This Year
- STRO N/A
- BMEA N/A
- Revenue Next Year
- STRO N/A
- BMEA N/A
- P/E Ratio
- STRO N/A
- BMEA N/A
- Revenue Growth
- STRO 230.90
- BMEA N/A
- 52 Week Low
- STRO $1.70
- BMEA $3.61
- 52 Week High
- STRO $6.13
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- STRO 37.11
- BMEA 26.06
- Support Level
- STRO $1.80
- BMEA $3.74
- Resistance Level
- STRO $2.01
- BMEA $4.30
- Average True Range (ATR)
- STRO 0.16
- BMEA 0.40
- MACD
- STRO 0.03
- BMEA 0.01
- Stochastic Oscillator
- STRO 37.18
- BMEA 6.84
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.